Economic Evaluation of Senshio ® (Ospemifene) for the Treatment of Vulvovaginal Atrophy in Scotland

ConclusionOspemifene is a cost-effective intervention that has recently been accepted by the SMC for the treatment of postmenopausal women with moderate to severe VVA who are not candidates for local oestrogen.

http://link.springer.com/10.1007/s40258-020-00589-2

Source: Applied Health Economics and Health Policy - May 10, 2020 Category: Health Management Source Type: research